Leap Therapeutics (LPTX)
(Real Time Quote from BATS)
$2.05 USD
-0.15 (-6.82%)
Updated Jun 14, 2024 11:34 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Leap Therapeutics, Inc. [LPTX]
Reports for Purchase
Showing records 21 - 33 ( 33 total )
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Balance Sheet Strengthened; Adjust PT to $2.50 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Change to Focus on DKN-01; Lower PT to $3.25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging DKN-01 Data Updates; Lower PT to $7.50 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DKN-01 and TRX518 Clinical Updates Expected in 2H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Clinical Updates on DKN-01 and TRX518; Lower $10 PT on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRX518 and DKN-01 Continue to Demonstrate Clinical Benefit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Data Readouts and Another Collaboration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive DKN-01 Results in Esophagogastric Cancer at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Unclassified
Promising Early Results From TRX518 and DKN-01 Combination Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Unclassified
New Collaboration to Test TRX518 Combination Therapy ; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Unclassified
Clinical Programs Continue to Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Unclassified
Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Unclassified
Leaping Ahead With Novel Cancer Therapies; Initiate With Buy and $12.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S